A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subjects.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Asunaprevir

Criteria

Inclusion Criteria:

• Chronic HCV-1b infected patient

• HCV RNA viral load of ≥ 100,000 IU/mL at screening

• Ages 20 to 75 years

• Non-responder to Interferon plus Ribavirin therapy

• Patient who has been excluded from interferon/ribavirin therapy or intolerant for Interferon/Ribavirin therapy

Exclusion Criteria:

Patients who have -

• Hepatocellular carcinoma

• Co-infection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV)

• Severe or uncontrollable complication